Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $351000.0.

  • Cyclerion Therapeutics' Accumulated Expenses rose 833.33% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year increase of 833.33%. This contributed to the annual value of $283000.0 for FY2024, which is 6453.63% down from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Accumulated Expenses of $351000.0 as of Q3 2025, which was up 833.33% from $266000.0 recorded in Q2 2025.
  • Cyclerion Therapeutics' 5-year Accumulated Expenses high stood at $6.4 million for Q4 2021, and its period low was $266000.0 during Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' median Accumulated Expenses value was $2.0 million (recorded in 2023), while the average stood at $2.2 million.
  • As far as peak fluctuations go, Cyclerion Therapeutics' Accumulated Expenses skyrocketed by 4100.74% in 2022, and later crashed by 7831.91% in 2024.
  • Over the past 5 years, Cyclerion Therapeutics' Accumulated Expenses (Quarter) stood at $6.4 million in 2021, then plummeted by 62.51% to $2.4 million in 2022, then crashed by 66.5% to $798000.0 in 2023, then plummeted by 64.54% to $283000.0 in 2024, then rose by 24.03% to $351000.0 in 2025.
  • Its last three reported values are $351000.0 in Q3 2025, $266000.0 for Q2 2025, and $534000.0 during Q1 2025.